Dr. Andrew Saykin is one of the world’s leading authorities on neuroimaging, and his expertise is critical to diagnosing and understanding how Alzheimer’s disease progresses.
Some of his current research examines advanced imaging methods for early preclinical detection of Alzheimer’s, the neural basis of cancer chemotherapy-induced cognitive changes and the alterations in brain activity and connectivity in schizophrenia.
Dr. Saykin’s current research program focuses on the integration of structural, functional and molecular brain imaging with genomic and biomarker methods to study mechanisms of memory dysfunction and therapeutic response.
- Cancer Prevention and Control
- Neurodegenerative Disorders Research
- Neuroimaging (in vivo) Research
- Psychiatric Disorders Research